The Role of Circulating Tumor Dna (Ctdna) in Liquid Biopsy for Early Cancer Detection and Recurrence Prediction

Liquid Biopsy Circulating Tumor DNA (ctDNA) Early Cancer Detection Minimal Residual Disease (MRD) Tumor Recurrence Prediction Next-Generation Sequencing (NGS)

Authors

November 12, 2026

Downloads

Traditional tissue biopsies are invasive, limited by spatial heterogeneity, and difficult to perform serially. Liquid biopsy, specifically the analysis of circulating tumor DNA (ctDNA), offers a non-invasive alternative for real-time monitoring of tumor dynamics. Objectives: This study evaluates the clinical utility of ctDNA in early-stage cancer diagnosis and the prediction of minimal residual disease (MRD) and tumor recurrence. Methods: We conducted a systematic review and meta-analysis of clinical cohorts spanning early-to-late stage solid tumors (colorectal, lung, and breast cancers) utilizing next-generation sequencing (NGS) and digital droplet PCR (ddPCR). Results: ctDNA assays demonstrated a pooled sensitivity of 76.4% for early-stage screening, which significantly increased when paired with multi-cancer early detection (MCED) protein markers. For recurrence tracking, ctDNA positivity post-surgery predicted disease relapse up to 8.2 months ahead of conventional radiological imaging (HR = 4.35, p < 0.001). Conclusion: ctDNA serves as a highly specific biomarker for early detection and a powerful tool for monitoring postoperative molecular recurrence, paving the way for personalized oncology.